TrumpRx Prices Exceed UK Levels for One-Third of Drugs

U.S. President Donald Trump launched the TrumpRx.gov website in January 2026 as part of agreements with 16 drug manufacturers to align American prescription drug prices with those in other developed countries. However, a comparison of prices on the site with those paid by the United Kingdom's National Health Service reveals that costs for about one-third of the 54 listed drugs remain higher in the United States, including treatments for arthritis, diabetes and lung diseases.

The initiative stems from most-favored-nation pricing deals, which aim to cap U.S. prices at levels charged abroad. The United Kingdom agreed to increase its medicine spending to avoid potential U.S. tariffs on pharmaceuticals. Eight companies currently participate on the site, which provides direct-to-consumer cash discounts or links to manufacturer websites. These prices apply only to out-of-pocket payments and do not integrate with insurance plans, meaning they cannot count toward deductibles or copays for most Americans covered by private or government-sponsored insurance.

Specific examples highlight mixed results. Pfizer's Xeljanz for arthritis, AstraZeneca's Farxiga for diabetes and GlaxoSmithKline's...